Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAJC9 antisense RNA 1 (DNAJC9-AS1) is a long non-coding RNA (lncRNA) gene located on human chromosome 10 and annotated in major genomic databases (NCBI Gene ID: 414245, Ensembl: ENSG00000236756)[1][5][9]. It is transcribed as an antisense RNA relative to its neighboring DNAJC9 and MRPS16 genes. The known aliases for this gene include C10orf103 and bA537A6.3[1][5][6][9]. DNAJC9-AS1 is classified as a lncRNA, not as a protein-coding gene[2][9]. It is reported to be involved in **basic cellular processes** including cell proliferation, apoptosis, and migration[2]. The mechanistic details of its function are largely unexplored; however, like other lncRNAs, DNAJC9-AS1 is predicted to participate in **chromatin regulation** and **transcription factor modulation**[1]. These roles are based on dataset associations, histone modification site profiles, and transcription factor binding evidence at the gene’s promoter[1]. Clinical and experimental evidence for DNAJC9-AS1’s role in **disease** is limited. Some databases note a weak association with **glioma susceptibility**[9], and by analogy with other lncRNAs, there may be relevance in broader cancer contexts, but robust data are lacking[2]. There are **no known drugs** that directly interact with DNAJC9-AS1, nor established mechanisms of drug action, known biomarkers, or documented safety concerns[1][2][9]. This molecule is **not considered a conventional therapeutic target** (such as a receptor, enzyme, or transporter)[1][2][9]. Most research concerning DNAJC9-AS1 remains descriptive, focusing on expression profiles across tissues and cells, rather than on pharmacological or clinical targeting. In summary, **DNAJC9 antisense RNA 1 (DNAJC9-AS1)** is a long non-coding RNA with unclear and incompletely characterized molecular function, mainly implicated in general cellular regulatory processes and not considered a therapeutic target at present[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAJC9 antisense RNA 1 (DNAJC9-AS1).